Related Experiment Video

Updated: Jun 21, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

CARD15 gene variants and risk of reoperation in Crohn's disease patients

Giovanni Maconi1, Elisabetta Colombo, Gianluca Matteo Sampietro

  • 1Department of Clinical Sciences, L. Sacco University Hospital, Via G.B. Grassi, 74, Milan 20157, Italy. giovanni.maconi@unimi.it

The American Journal of Gastroenterology
|July 30, 2009
PubMed

Insights

Reoperation in Crohn's disease (CD) is linked to initial stenosis, not CARD15 gene variants. This finding suggests current prophylactic therapies do not need adjustment based on CARD15 genotype in CD patients.

Area of Science:

  • Gastroenterology
  • Genetics
  • Surgical Research

Background:

  • Crohn's disease (CD) management involves surgery, with reoperation rates varying.
  • CARD15 gene variants are known risk factors for CD, associated with disease phenotype and initial surgery risk.
  • Previous research on CARD15 variants and CD reoperation is limited and conflicting.

Purpose of the Study:

  • To investigate risk factors for reoperation in Crohn's disease patients.
  • To specifically evaluate the association between CARD15 gene variants and the need for reoperation.

Main Methods:

  • A cohort of 253 CD patients undergoing surgery was analyzed across four Italian IBD centers.
  • Data collected included clinical characteristics, surgical indications, operation type, and time to reoperation.
  • CARD15 gene variants were assessed via DNA sequencing, and Cox regression analyzed recurrence factors.

Main Results:

  • Surgical recurrence occurred in 35.1% of patients.
  • Reoperation was significantly correlated only with stenosis as an indication for initial surgery.
  • CARD15 variants were present in 36.0% of patients but showed no significant association with recurrence rate or timing.

Conclusions:

  • Stenosis at initial surgery is a significant predictor of reoperation in Crohn's disease.
  • CARD15 gene variants do not appear to influence the rate or timing of reoperation in CD patients.
  • Current findings do not support modifying prophylactic treatment strategies based on CARD15 genotype.
Abstract

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...